A Phase I, Open-Label Dose Escalation and Dose Expansion Study of Intravenous GFH009 SingleAgent in Patients with Relapsed/Refractory Hematologic Malignancies
The purpose of this study is to assess the safety, effectiveness, pharmacokinetic ([PK] how long the drug is in your body and how it is metabolized) and pharmacodynamics ([PD] where does the drug go in your body and what is its biological effect) of the study drug, GFH009, in patients with relapsed or refractory hematologic malignancies including acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or other lymphomas. This is the first time GFH009 is being studied in humans.
Are you Eligible? (Inclusion Criteria)
- or older.
- 2. Have cytological or histologically confirmed relapsed or refractory hematologic
- 3. No history of HIV infection.
- 4. No Chronic or active hepatitis B or hepatitis C virus infection.